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increasingly performed. NC-IVF and conventional gonadotropin-
stimulated IVF (cIVF) should not be understood as competing
treatments, but as complementary treatments with different
target groups and to some extent other indications. NC-IVF is
particularly interesting for couples who wish to save money, wish
a treatment with as few risks as possible and for women who
would like to avoid selection and cryopreservation of embryos. NC-
IVF therefore contributes to the concept of individualized and
patient-oriented therapy. The time to pregnancy is slightly longer
than with conventional IVF. NC-IVF is particularly suitable for
younger women and for women with a very low ovarian reserve.
In this article, the principles of NC-IVF, i.e. monofollicular IVF
without gonadotropin stimulation, are described and the technical
differences to cIVF, advantages and disadvantages, perinatal
outcome and indications for NC-IVF are highlightened.
© 2018 The Author(s). Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The world's ﬁrst successful IVF pregnancy occurred after natural-cycle IVF (Natural Cycle IVF, NC-
IVF), i.e. after IVF without the use of exogenous hormones and with natural folliculogenesis. Notyn€akologische Endokrinologie und Reproduktionsmedizin, Freidbühlstrasse
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stimulation and the associated transfer of multiple embryos (conventional IVF, cIVF).
The wish that many women express to undergo as little hormonal treatment as possible,
progress was made in the implementation of NC-IVF and new insights into the beneﬁts of this
treatment are now leading to couples expressing increasing interest in this therapy, which is
becoming ever more common in some countries [1]. In contrast, among physicians NC-IVF is often
discussed controversially, as it is considered to be a therapy which competes with conventional IVF
therapy. However, NC-IVF and cIVF are completely different forms of treatment which can only be
compared to a limited extent. NC-IVF and cIVF should therefore be understood as complementary
IVF treatments that expand the treatment spectrum in terms of individualized, patient-oriented
treatment.
In this article, the principles of NC-IVF, i.e. monofollicular IVF without gonadotropin stimulation are
described and the technical differences to cIVF, advantages and disadvantages, perinatal outcome and
indications for NC-IVF are highlighted.Principle and deﬁnition
The principle of NC-IVF is based on the concept of natural follicle recruitment and selection and an
unsupported luteal phase. This avoids gonadotropin injections and luteal phase support. The im-
plantation rate per fertilized oocyte seems to be higher, possibly due to better oocyte quality and
unaffected endometrial function. However, it needs to be stressed that the high number of oocytes
collected in most cIVF cycles can overcompensate these disadvantages resulting in shorter time to
pregnancies in cIVF. Furthermore, the term “natural” is only related to themenstrual cycle, whereas the
process of oocyte fertilization requires the same laboratory techniques as in cIVF such as insemination
or intracytoplasmic sperm injection (ICSI).
According to the deﬁnition by the International Society for Mild Approaches in Assisted Repro-
duction, ISMAAR [2] published in 2007, Natural Cycle IVF is deﬁned as IVF without any medication. The
term “modiﬁed NC-IVF” includes some medication to reduce the likelihood of cycle cancellation, such
as human chorionic gonadotropins (hCG), to induce ﬁnal oocyte maturation and/or gonadotropin
releasing hormone (GnRH) antagonists (GnRHant) with or without follicle stimulation hormone (FSH)
or human menopausal gonadotropin (hMG) as addback therapy. According to Nargund et al., 2007 [2],
luteal phase should be given if GnRHant are applied.
These deﬁnitions are currently under review by ISMAAR and it can be expected that they will be
slightly modiﬁed. The reasons are obvious. Firstly, NC-IVF almost always requires ovulation triggering
with HCG as otherwise the technique is inefﬁcient, secondly, single injections of GnRHant do not
require gonadotropin add-back, thirdly, the likelihood of cycle cancellation can also be reduced by
other medication such as non-steroidal anti-inﬂammatory drugs (NSAIDs) and fourthly, luteal phase
support is not required using these treatment strategies.
Therefore, in this manuscript NC-IVF will be deﬁned as any IVF without gonadotropins or
any other stimulation of follicular growth, allowing natural follicle recruitment and selection
and as IVF without any luteal phase support. However, medications such as single GnRHant
injections, NSAIDs and very low dosages of clomifene citrate (CC) to avoid premature LH surge
as well as hCG to trigger ovulation can be applied (Fig. 1). Clinically this kind of NC-IVF leads in
most cases in the development of only one follicle and can therefore also be deﬁned as
“monofollicular IVF”.
Conventional IVF (cIVF) is deﬁned in this article as any IVF with gonadotropin stimulation and
GnRHant or GnRH agonists to prevent LH surge in order to generate many follicles, without preim-
plantation genetic testing. cIVF can also be deﬁned as “polyfollicular IVF”.
Minimal stimulation IVF is deﬁned as any IVF therapy with some stimulation of follicular growth
and can also be described as “oligofollicular IVF”.
All calculations and comparisons in this article, which only focuses on NC-IVF compared to cIVF, are
based on these deﬁnitions.Please cite this article as: vonWolff MThe role of Natural Cycle IVF in assisted reproduction, Best Practice
& Research Clinical Endocrinology & Metabolism, https://doi.org/10.1016/j.beem.2018.10.005
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Fig. 1. NC-IVF treatment protocol.
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Follicle monitoring
NC-IVF can only be an alternative to cIVF if treatment is kept to a minimum, i.e. with the least
possible effort for the patient (Fig. 1). Essential here are the number of follicular growth monitoring. An
exact evaluation of the follicular growthmonitoring performed has so far only been done in the studies
by von Wolff et al., 2014a [3] and H€ammerli et al., 2017 [4]. The ﬁrst follicular growth monitoring was
performed during a 28-day cycle between the 10th and 12th cycle day. When the follicular diameter
was expected to reach at least 16 mm and estradiol (E2) concentrationwas expected to be 700 pmol/
L, 5000 IU human chorionic gonadotropin (HCG) was administered subcutaneously 36 h before oocyte
retrieval. This procedure required 1.2 follicular monitoring sessions per cycle. It was comparatively
determined that arithmetically, 7.8 consultations would be required for 3 NC-IVF cycles compared to 5
consultations for a cIVF with a fresh transfer [5]. H€ammerli et al., 2017 [4] compared the psychological
burden of NC-IVF therapy (up to 3 NC-IVF cycles) with cIVF therapy (1 therapy cycle) and also analysed
the number of consequent consultations. Therewere 5.5 consultations for c-IVF and 6.2 for NC-IVFwith
the same pregnancy rate in both study arms. Thus, the number of consultations required for one cIVF
cycle is equivalent to 2e3 NC-IVF cycles.Control of premature ovulation
The transfer rate is crucial for the effectiveness of the NC-IVF. This depends essentially on the egg
cell collection rate and thus on the number of available follicles. Since the oocyte must be harvested as
late as possible to minimize the risk of collecting immature oocytes, there is a risk that ovulation has
already taken place at the time of scheduled oocyte collection. Various techniques have been described
to reduce this risk.
Injection of a GnRH antagonist (GnRHant)
GnRHant can be used if the LH surge has not yet started and ovulation should be postponed by one
day. If more than one injection is administered, gonadotropins must be added in addition [6] as notPlease cite this article as: vonWolff MThe role of Natural Cycle IVF in assisted reproduction, Best Practice
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this no longer corresponds to NC-IVF. An injection of GnRHant can be used if the follicular puncture is
to be delayed by one day, e.g. for logistical reasons, or if the follicular size is still <15 mm, but the E2
concentration is already so high that an LH surge is expected.
Administration of non-steroidal anti-inﬂammatory drugs (NSAIDs)
NSAIDs, e.g. indomethacin or ibuprofen, may be used to postpone ovulation by several hours both
before and at the onset of LH surge [7e9]. NSAIDs inhibit cyclooxygenase (COX) which catalyses the
synthesis of PGE2, a key prostaglandin in the inﬂammatory cascade of ovulation. According to Bienz
et al., 2018 [10], orally administered ibuprofen penetrates the follicle, where it leads to similar con-
centrations as in the blood serum. In the follicular ﬂuid, ibuprofen leads to a (non-signiﬁcant) reduction
in the concentration of PGE2 and a reduction of inﬂammatory cytokines such as interleukin 8 [10]. This
seems to inhibit the LH surge-induced inﬂammatory process and thus the break-down of the follicular
wall. Indomethacin [8] ibuprofen [10] and other NSAIDs are used. Ibuprofen at a dose of 3  400 mg
does not cause any gastrointestinal side-effects [11]. Although NSAIDs are used in each cycle in some
studies [8], this approach results in unnecessary drug administration in most cases. The administration
of NSAIDs can be minimized if they are only used if a commencing LH surge is detected. Kohl et al. [9],
showed that when ibuprofen at a dose of 3 400mgwas given at an incipient LH surge (LH¼ 10e20 U/
l) and oocyte collection took place 2 days and thus about 48 h later, the rate of premature ovulationwas
only 20.6%. Transfer rate per initiated cycle was 46%, pregnancy rate per transfer was 27.6% and per
initiated cycle 12.7%.
These numbers were similar to a control group without premature LH surge and without ibuprofen,
demonstrating that oocyte competence does not seem to be negatively affected by ibuprofen.
Preovulatory administration of low-dose clomifene citrate (CC)
Low dose CC can be used prophylactically to delay the LH surge. Clomiphene contains a mixture of
two isomers, about 1/3 in the zuclomifene (cis) form and 2/3 in the enclomifene (trans) form. Enclo-
mifene probably has estrogen antagonist effects and inhibits the positive feedback at the level of the
hypothalamus [12]. As enclomifene is eliminated rapidly within around 24 h [13], clomifene tablets
need to be given once a day until the day of ovulation triggering. In contrast, clomifene which probably
has estrogen agonist actions at the pituitary level [12], is eliminated at a much slower rate [13], which
can clinically result in cyst formation in consecutive stimulation cycles, especially when higher doses
were applied.
In a clinical study, CC reduced the rate of premature ovulation from 27.8% without CC to 6.8% and
increased the transfer rate from 39.8% to 54.4% respectively [3]. Pregnancy rates per transfer were
25.0% with and 27.9% without CC and per initiated cycle 13.6% and 11.1%, respectively. Use of CC
resulted in mild ﬂushes and headache in 5% of patients. Persisting ovarian cyst formation was not
observed.
Follicle aspiration
The transfer rate depends crucially on the egg cell collection rate. To increase the oocyte collection
rate, follicular ﬂushing is carried out in NC-IVF by several working groups.
For cIVF with a multifollicular response [14] and a low response [15], follicular ﬂushing has no
additional beneﬁt. However, in monofollicular NC-IVF, follicular ﬂushing appears to increase the IVF
success rate.
VonWolff et al., 2013 [16], used amonoluminal 19G aspiration needle and ﬂushed the follicles three
times. By ﬂushing, the total oocyte yield increased by 80.9% from 44.5% to 80.5%. Oocyte yield per
aspiration was 44.5% in the aspirate, 20.7% in the 1st ﬂush, 10.4% in the 2nd ﬂush and 4.3% in the 3rd
ﬂush. Flushing increased the transfer rate by 91.0% from 20.1% to 38.4%.
However, this is the only study to date on the effect of ﬂushing in NC-IVF and it is a retrospective
study. The results of a prospective randomized study by our research group, comparing aspiration
followed by 5-fold follicular ﬂushing compared to aspiration without ﬂushing in NC-IVF, are expected
in 2019(ClinicalTrials.gov Identiﬁer: CT02641808).Please cite this article as: vonWolff MThe role of Natural Cycle IVF in assisted reproduction, Best Practice
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IVF requires luteal phase support until the pregnancy test results positive [17]. The supra-
physiological E2 concentrations in particular lead to a suppression of LH release, resulting in a luteal
body insufﬁciency [18].
Although these factors do not apply to NC-IVF, many physicians still perform luteal phase support,
especially since it cannot be ruled out that the function of the corpus luteum is limited by the follicular
aspiration and follicle ﬂushing. However, von Wolff et al., 2017 [19] showed that the luteal phase is
unaffected by follicular aspiration and repeated follicular ﬂushings. They conducted a prospective
cohort study and compared women aged 18e40 who underwent both a reference cycle with hCG-
induced ovulation as well as a ﬂushing cycle with hCG-induced ovulation, followed by follicular
aspiration with follicle ﬂushings. The length of the luteal phase and luteal concentrations of proges-
terone and estradiol were analysed. Duration of the luteal phase was (median [IQR]) 13 days [12; 14.5]
in reference cycles, and in ﬂushing cycles 14 days [12.5; 14.5]. Progesterone and estradiol concentra-
tions were also not different, indicating that follicle aspiration and ﬂushing of follicles does not have a
negative effect on the luteal phase.
Thus, luteal phase support in NC-IVF therapy is not usually required. Because vaginal administration
of micronized progesterone causes troublesome side effects in up to 50% of women [20,21], this is a
relevant relief for many women. Whether women >40 y or women with a shortened luteal phase of
<12 days could beneﬁt from luteal phase support is still unclear.
Psychological stress induced by NC-IVF
cIVF imposes substantial distress [22] and many couples stop treatment prematurely because of
psychological stress, thus reducing the likelihood of success [23]. In addition to the pressure to succeed,
stress-inducing factors include daily injections, treatment risks and costs, but also factors such as
embryo selection and cryopreservation of embryos [24].
In NC-IVF almost no injections are required, the cost per cycle is lower [5], and embryo selection and
cryopreservation are not required. However, about 3 times as many treatment cycles are required per
pregnancy achieved [25]. Since all these factors can inﬂuence the treatment stress, H€ammerli et al.,
2018 [26] investigated psychological distress during and after cIVF and after up to three NC-IVF
therapies. They showed that NC-IVF patients had a signiﬁcantly lower level of depression and a
higher satisfaction with the treatment after the treatment cycles than cIVF patients.
NC-IVF therefore appears to cause less treatment-induced stress than cIVF. It should be noted that
this study was conducted in Switzerland, where IVF treatments are not reimbursed by the health in-
surance system. Therefore, it cannot be ruled out that in other countries with other reimbursement
systems and in other cultures, the treatment stress of the various IVF therapies will be perceived
differently.
Costs of NC-IVF
The costs of an NC-IVF cycle are signiﬁcantly lower than those of a cIVF cycle due to the lack of
gonadotropin stimulation, avoidance of anaesthesia and less effort in the IVF laboratory. A couple with
good prognostic factors for successful therapy has a chance of becoming pregnant after only 1e2 NC-
IVF cycles, therefore making considerable cost savings.
However, for a cost comparison, it is not the cost per cycle that should be calculated, but the cost per
pregnancy achieved and, ideally, even per birth achieved. Thus, according to Sunkara et al., 2016 [25],
about 3 NC-IVF therapy cycles are required to achieve the same pregnancy rate as with one cIVF
therapy.
VonWolff et al., 2014b [5] determined the cost per pregnancy achieved in NC-IVF and cIVF. The NC-
IVF was based on own data fromwomen aged 35.4 ± 4.7 y (21-42 y), 1.2 follicular controls per cycle, a
transfer rate of 54.3% and a pregnancy rate of 13.6% per initiated cycle. For cIVF, 3 consultations per
fresh cycle and 2 consultations per thawing cycle were calculated. The pregnancy rate was calculated
for cIVF according to the ESHRE IVF registry [27] with 30% for a fresh cycle and 20% for a thawing cycle.Please cite this article as: vonWolff MThe role of Natural Cycle IVF in assisted reproduction, Best Practice
& Research Clinical Endocrinology & Metabolism, https://doi.org/10.1016/j.beem.2018.10.005
M. von Wolff / Best Practice & Research Clinical Endocrinology & Metabolism xxx (xxxx) xxx6Based on these guidelines, the cost per pregnancy achieved when performing NC-IVF is 15% lower than
for cIVF.
Groen et al., 2013 [28], determined the cost per birth achieved for NC-IVF and cIVF. Based on the
success data from twomajor Dutch centres and the cost of 6 NC-IVF cycles and a complete cIVF using a
single embryo transfer, they compared two techniques that mainly produced no multiple births. The
age of womenwas 18e36 y, the delivery rate per cycle was 6.0% for NC-IVF and 22.7% for cIVF. Based on
these numbers, the cost per birth achieved when performing an NC-IVF was 12% higher thanwith cIVF.
In summary, the cost per cycle for the NC-IVF is much lower than for cIVF. However, the overall costs
of NC-IVF and cIVF seem to be similar for each pregnancy and birth achieved.
Success rates of NC-IVF
A number of studies has shown that the implantation rate per oocyte collected during cIVF is lower
than for NC-IVF. The reasons for this are unclear. A dysregulated endometrium due to supra-
physiological estradiol concentrations [29] and an altered endocrine milieu due to reduced LH con-
centrations [30] are suspected to be responsible. Embryo quality also appears to be better in NC-IVF
[31e33], although the aneuploidy rate of the embryos is not lower [34].
However, the success rates of NC-IVF can only be comparedwith cIVF to a limited extent, since these
are completely different therapies. Accordingly, no study has been conducted with a head-to-head
comparison of both therapies.
It should also be noted that one cycle of a cIVF, including timing and the often-used subsequent
wash-out or recovery cycle takes 3 months, during which three NC-IVF cycles can be performed. It
therefore makes more sense to calculate the success rate per unit of time or per cost (see below) and
not per initiated cycle.
The data on the success rate are confusing, as the published studies are often small, various IVF
therapy protocols were used, the success rates per transfer rather than per cycle are given [35] and IVF
therapies were performed under unfavourable conditions such as in low responders [36], or only after
the performance of several classical IVF treatments because of national reimbursement policies as in
Germany [37].
According to registry data [38] and data from centres also offering NC-IVF as the primary IVF
therapy in normal responders [39,3], the pregnancy rate per initiated cycle is on average between 10
and 15%. However, as with cIVF, the success rates are strongly age-dependent and are below 10% in
women >38 years [40].
Several studies have calculated how many NC-IVF cycles are required to achieve the same success
rate as cIVF. According to [25] Sunkara et al., 2.9e3.5 NC-IVF cycles are required. In a study by H€ammerli
et al., 2018 [26], 2e3 NC-IVF cycles were required. These ﬁgures roughly correspond with the calcu-
lation by von Wolff et al., 2014b [5], who calculated that the time to pregnancy with NC-IVF is 30%
longer than with cIVF because of the monthly but less effective cycles.
The success rate of cIVF naturally depends very much on the number of oocytes which can be
collected. As a result, the success rate in low-responders undergoing NC-IVF is higher than for c-IVF
[40], whereas women around 40 years of age with a high ovarian reserve should beneﬁt from cIVF
because of the age-related decline in chances of success (Fig. 2).
In summary, the success rate of NC-IVF per initiated cycle is signiﬁcantly lower than for c-IVF. With
consistent monthly NC-IVF treatment, which allows about 3 cycles in the same time period as one cIVF,
the success rate per unit time is only slightly reduced. With low responders, the effectiveness of NC-IVF
is higher than with cIVF. Older women with a high ovarian reserve beneﬁt more from cIVF than from
NC-IVF.
Perinatal outcome after NC-IVF
Pregnancies after IVF are at a risk of adverse perinatal outcomes compared with those conceiving
naturally [41,42]. This might be due to the underlying infertility cause, but also to the IVF procedure
itself, which includes ovarian stimulation, in-vitro gamete handling, embryo culture and cryopreser-
vation of embryos [42]. Many of these factors apply to NC-IVF, NC-IVF but not ovarian stimulation andPlease cite this article as: vonWolff MThe role of Natural Cycle IVF in assisted reproduction, Best Practice
& Research Clinical Endocrinology & Metabolism, https://doi.org/10.1016/j.beem.2018.10.005
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Fig. 2. Decision aid for patient orientated IVF therapy.
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concentrations in the blood circulation, which lead to dysfunction of the endometrium and placenta. In
animal models it has been shown that high serum estradiol levels have a negative effect on uterine
spiral artery invasion into the placenta [43]. Furthermore, supraphysiological estradiol concentrations
may result in an edematous endometrium, impairing trophoblast differentiation and abnormal
placentation [44]. These effects might be causative for the increased risk of low birth weight, LBW
(<2500 g) (RR 1.95, 95% CI 1.03 to 3.67) in cIVF versus NC-IVF therapies as shown in a meta-analysis
[45]. Furthermore, the risk for small gestational weight for age, SGA (birth weight <10th percentile),
is also increased in cIVF compared to NC-IVF therapies [46]. We conﬁrmed an increased risk of SGA in
cIVF versus NC-IVF and speciﬁed a supraphysiological E2 concentration of 10 000 pmol/l to be a risk
factor (aOR 3.78, 95% CI 1.1e13.2, p ¼ 0.037) [47].
The second factor, cryopreservation of embryos, when compared to a fresh transfer in stimulated
IVF, leads to an increased risk (RR) of hypertensive disorders of pregnancy (1.29; 95% CI 1.07e1.56),
large baby for gestational age (1.54; 95%). CI 1.48e1.61) and a high birth weight (1.85, 95% CI 1.46e2.33)
[48]. Since the child's weight is also increased in comparison to natural conception (AOR ¼ 1.31 95% CI
1.20e1.43 p < 0.001) [49], cryopreservation per se seems to have an effect. Whether this effect is due to
epigenetic modiﬁcations due to the freezing process is not yet clear.
In summary, the perinatal outcome of NC-IVF is probably better due to the lack of stimulation and
the associated physiological estradiol concentrations as well as the lack of cryopreservation of the
embryos than in classical, stimulated IVF. However, whether this improved outcome is functionally and
clinically relevant for the children in later years of life has yet to be shown in further studies.Indications for and against NC-IVF
The indications for or against NC-IVF are based on the individual wishes of the couple as well as on
the individual chances of success and therefore on the objective prognosis factors of IVF therapy.
The wishes of the couple, especially the woman, are often individual but also culturally very
different and are shaped by previous experiences with IVF therapies, as well as religious reasons. Some
women develop a variety of side effects during cIVF, so they refuse gonadotropin stimulation in further
treatments. Some couples do not want embryo selection and cryopreservation of embryos for religious
reasons. On the other hand, some couples seek the treatment with the shortest time to pregnancy and
are willing to accept the risk of multiple births.
Irrespective of individual wishes, the success of the treatment is usually, if not always, at the centre
of the decision-making process. Because of this, it may be useful to consider the individual needs asPlease cite this article as: vonWolff MThe role of Natural Cycle IVF in assisted reproduction, Best Practice
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only 1e2 follicles would form under gonadotropin stimulation, makes little sense. In contrast, for a
woman in her forties with a well preserved ovarian reserve, treatment with the shortest time to
pregnancy and therefore cIVF is preferable. A logarithm that considers the individual wishes as well as
the medical prerequisites for the indication is shown in Fig. 2.
In contrast to the individual wishes, prognostic factors for the occurrence of a pregnancy can be
objectiﬁed. For cIVF, a meta-analysis [50] revealed a negative association between pregnancy and fe-
male age (OR 0.95, 95% CI: 0.94e0.96), duration of subfertility (OR 0.99, 95% CI: 0.98e1.0) and basal FSH
(OR 0.94, 95% CI: 0.88e1.0). It also described a positive associationwith the number of oocytes (OR 1.04,
95% CI: 1.02e1.07) and better embryo quality was also associated with higher pregnancy chances. The
relevance of the cause of infertility seems to be limited as shown by an Australian registry study [51],
which showed a success rate of 22.0% in couples with a male factor compared to 19.2% with a female
factor (see Table 1.
The prognostic factors for NC-IVF have so far only been examined in two studies (Table 2). Gonzales-
Foruria et al., 2016 [52], found age (OR 0.93, 95% CI: 0.88e0.98) but not infertility to be a prognostic
factor in NC-IVF. This study investigated pregnancy but not live birth rates and included varying
numbers of IVF cycles per patient and gonadotropin stimulated cycles. Von Wolff et al. [40] only
included one cycle per patient and analysed both pregnancy and live birth rates. This study included
only transfer but not initiated cycles. Multivariate logistic regression analysis revealed high female age
(OR 0.87, 95%: CI 0.78e0.95) and long duration of infertility (OR 0.61, 95% CI: 0.42e0.86) as predictors
for live birth rates but not AMH concentration and infertility factors.
Controversies of NC-IVF
The comparison of NC-IVF with cIVF is often based less on scientiﬁc evidence than on philosophical
considerations such as “natural” versus “artiﬁcial” and how effective the two IVF treatments really are.
That such a comparison does not make sense, is obvious. Follicle recruitment and selection, as well
as the luteal phase of NC-IVF are actually “natural”; however, the process of egg fertilization is just as
“artiﬁcial” as in cIVF. Furthermore, “effectiveness” can also be considered from different angles. The
advocate of cIVF will only consider the pregnancy rate per cycle and transfer under “effectiveness”. The
advocate of NC-IVF, however, would point out that “effectiveness” can also be related to the costs, the
treatment stress, the risks, etc. and emphasize that factors other than the pure pregnancy rate per cycle
and transfer are also relevant.
The controversies regarding NC-IVF versus cIVF are consequently based on different perspectives
and on different sets of values.
A blanket approval or rejection of NC-IVF or cIVF does not make sense, and the decision for or
against one of the two therapies should be based on the biological and medical conditions and the
wishes of the couple, taking into account the advantages and disadvantages of the treatments (Table 2).
Such a patient-oriented approach is exempliﬁed in Fig. 2.
Due to the diversity of NC-IVF and cIVF, a head to head comparison of NC-IVF versus cIVF, as
required by many scientists, does not make sense. On the one hand, it will hardly be possible to
recruit enough patients for such a prospective randomized study, and on the other hand theTable 1
Positive prognostic factors for NC-IVF and cIVF for treatment success [40,50,52].
NC-IVF
Low female age
Short duration of infertility
cIVF
Young female age
Short duration of subfertility
Low basal FSH
High number of oocytes
High embryo quality
Please cite this article as: vonWolff MThe role of Natural Cycle IVF in assisted reproduction, Best Practice
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Table 2
Advantages and disadvantages of NC-IVF compared to cIVF.
Advantages of NC-IVF compared to cIVF
NC-IVF treatment can be performed every month
Daily injections are not required
Luteal phase support is not required
The endometrium is not negatively affected by supraphysiological estradiol concentrations
Adjuncts to improve endometrial function are not required
Anaesthesia is not required for follicle aspiration
Cryopreservation of zygotes or embryos is not necessary; discarding of surplus embryos is not required
The average psychological treatment distress seems to be lower
Ovarian hyperstimulation syndromes cannot occur
Multiple pregnancies rarely occur
The perinatal outcome is better
The costs per cycle are much lower
Disadvantages of NC-IVF compared to cIVF
NC-IVF cycles require more ﬂexibility for the IVF centre, for the women and - if sperm is not cryopreserved e also for the
man
The average time to pregnancy is longer in NC-IVF
The average total treatment costs per achieved live birth are not lower than in cIVF
M. von Wolff / Best Practice & Research Clinical Endocrinology & Metabolism xxx (xxxx) xxx 9question arises as to what the main outcome criterion of such a study should be. The pregnancy
rate per cycle, per transfer, or per unit of time are just a few of the possible criteria, along with a
variety of other outcome criteria, such as complication rates, multiple treatment rate, stress of
treatment, cost, and many more. It makes more sense to further optimize NC-IVF with the help of
further studies and to further reﬁne the range of indications since they are less about competing
but complementary techniques.
Some reproductive physicians might argue that cIVF provides the opportunity to perform a
thawing cycle a lower costs and with less patient's stress and risks which should be taken into
account if both techniques are compared. However, this is a complicated issue as thawing cycles
still cost quite a lot, as the patient's stress has never been compared in thawing cycles and NC-IVF
cycles and as thawing cycles could impose a still poorly understood risk to the children due to the
freezing procedure [48]. The putative risks of freezing embryos also need to be taken into account if
the “freeze all” strategy is discussed to avoid ovarian hyperstimulation syndrome. Indeed, this
strategy avoids this maternal risk which might be an argument for cIVF, but as long as the fetal
risks of the freezing process are not sufﬁciently understood, this argument should be used with
care.
Another controversy may be based on different expertise in NC-IVF treatment. Since NC-IVF rep-
resents a completely different form of treatment, it also requires completely different knowledge and
experience in order to achieve a high success rate with minimum effort for the couple. cIVF is based on
treatment protocols that can be widely used consistently in all women. NC-IVF, however, requires a
deeper understanding of basic endocrinology and individualized treatment.
Conclusion
NC-IVF and cIVF are basically different forms of treatment with different costs, burdens and risks.
They both require speciﬁc knowledge and experience as well as various logistical requirements on the
part of the IVF Centre. The treatments should not compete with each other but should be seen as
complementary. They can be offered based on the medical prerequisites and wishes of the couple and
contribute to personalized and patient-oriented IVF treatment.
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Practice points
Natural cycle IVF (NC-IVF) and conventional, gonadotropin IVF (cIVF) are not competing
treatments but complementary treatments with different indications, advantages and
disadvantages.
NC-IVF contributes to an individualized and patient orientated IVF therapy.
NC-IVF tends to be cheaper than cIVF, but time to pregnancy is on average longer.
NC-IVF seems to be more successful in low responders but less successful in older women
with a high ovarian reserve.
NC-IVF require specific knowledge and experience to achieve low treatment burden and high
success rates.
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